Zoran is a Internal Medicine Resident at Institute of Rheumatology, School of Medicine, University of Belgrade, undertaking a PhD at the same institution. His work primarily focuses on investigating the adjunctive treatment for fibromyalgia and its influence on different outcomes, such as gait and balance.Zoran is a member of the Country Liaison Sub-committee.
|Poster 0822 | Sunday, 12.11.23 16.00|
Abstracts: Osteoarthritis I Clinical Trials
Author: Hannani, M (Denmark)
Title: FROM BIOMARKERS TO ENDOTYPES: DATA-DRIVEN IDENTIFICATION OF KNEE OSTEOARTHRITIS PATIENTS SUBTYPES
This study shows that identifying knee osteoarthritis endotypes could facilitate the development of more precise treatments..
|Poster 2008 | Tuesday 14.11.23 09:00 AM|
Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster
Author: Curtis, J (USA)
Title: COMPARATIVE EFFECTIVENESS OF DENOSUMAB VERSUS ALENDRONATE AMONG POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN THE U.S. MEDICARE PROGRAM
This retrospective observational study evaluated the comparative effectiveness of Denosumab versus alendronate in reducing fracture risk among postmenopausal women with osteoporosis in almost half million patients.
|Poster 2531 | Sunday, 14.11.23 16.00|
Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science
Author: Palmowski, A (Germany)
Title: PROTON PUMP INHIBITOR USE IS ASSOCIATED WITH IMPAIRED BONE MINERAL DENSITY BUT NOT BONE MICROARCHITECTURE IN PATIENTS WITH INFLAMMATORY RHEUMATIC AND MUSCULOSKELETAL DISEASES TAKING GLUCOCORTICOIDS
Loss of bone mineral density seems to be driving the increased fracture risk seen with proton pump inhibitor use in patients with inflammatory rheumatic diseases.
|Oral 0820 | Sunday, 12.11.23 16.00|
Abstracts: Osteoarthritis I: Clinical Trials
Author: Yazici, Y (USA)
Title: RADIOGRAPHIC AND PAIN OUTCOMES FROM A PHASE 3 EXTENSION STUDY EVALUATING THE SAFETY AND EFFICACY OF LORECIVIVINT IN SUBJECTS WITH SEVERE OSTEOARTHRITIS OF THE KNEE (OA-07): 36 MONTH SINGLE BLIND AND PLACEBO CROSSOVER PHASE RESULTS
A Phase 3 extension study evaluated Lorecivivint safety and efficacy in patients with severe knee osteoarthritis.
|Oral 1183 | Monday 13.11.23 09:00 AM|
Osteoarthritis – Clinical Poster II
Author: Samuels, J (USA)
Title: COLCHICINE FOR TREATMENT OF OSTEOARTHRITIS OF THE KNEE—UPDATED DATA FROM A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
This study established a connection between NETosis findings and disease activity in Behcet disease, suggesting the need for further studies.
|Oral 2126 | Tuesday 14.11.23 11:00 AM|
Author: Mok, C C (Hong Kong)
Title: ROMOSOZUMAB VERSUS DENOSUMAB IN HIGH-RISK PATIENTS TREATED WITH GLUCOCORTICOIDS: INTERIM 12-MONTH RESULTS FROM A PILOT RANDOMIZED CONTROLLED TRIAL
Romosozumab was superior to denosumab concerning the increase in spine bone mineral density and may offer a new treatment option for GIOP in high-risk patients.